Related Experiment Video
Updated: May 23, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[New therapies in pediatric rheumatology]
Felicitas Bellutti Enders1, Annette Von Scheven-Gête, Federica Vanoni
1Unité romande de rhumatologie pédiatrique, CHUV, Lausanne.
Abstract:
Biotherapies are recent treatments, which target molecules implicated in the pathogenesis of inflammatory diseases. In pediatric rheumatology, we use anti-TNF-alpha and abatacept in JIA patients with polyarticular involvement, whereas anti-IL-6 and anti-IL-1 blockers are efficacious in the systemic form of JIA and other auto-inflammatory conditions. These new treatments have significantly improved the control of articular and systemic inflammation and the prognosis of rheumatic diseases. Their effect and their safety on the long-term need to be assessed on large cohorts of patients. Due to the impact of these chronic illnesses on the young patient and its family, and the required specific knowledge, the care of these children should be provided by a multidisciplinary team linked to a centre of competence.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Rheumatic Heart Disease III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmacokinetics in Pediatric Patients: Drug Distribution